港股异动 | 维立志博-B(09887)涨超5% 维利信?获欧盟委员会授予孤儿药认定
LEADS BIOLABS-BLEADS BIOLABS-B(HK:09887) Zhi Tong Cai Jing·2026-01-23 06:28

Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, reaching 55.2 HKD, following the announcement of orphan drug designation for its drug Valiant (Oparatuzumab, LBL-024) by the European Commission [1] Group 1 - On January 22, Valiant Pharmaceuticals-B announced that the European Commission granted orphan drug designation for its PD-L1/4-1BB bispecific antibody, Valiant, for the treatment of pulmonary neuroendocrine carcinoma [1] - This designation is a significant milestone, marking the second orphan drug designation for Valiant after receiving similar recognition from the U.S. Food and Drug Administration (FDA) [1] - The announcement reflects Valiant's progress in its global development efforts [1]